Cary Street Partners’s MIRA Pharmaceuticals MIRA Stock Holding History

Cary Street Partners’s Portfolio MIRA Stock Details MIRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.46K	Hold	10,000	–	–	﹤0.01%	1071
2026 Q1	$10.7K	Hold	10,000	–	–	﹤0.01%	971
2025 Q4	$15.1K	Hold	10,000	–	–	﹤0.01%	963
2025 Q3	$13.6K	Hold	10,000	–	–	﹤0.01%	909
2025 Q2	$12.1K	Hold	10,000	–	–	﹤0.01%	883
2025 Q1	$9.8K	Hold	10,000	–	–	﹤0.01%	847
2024 Q4	$11.4K	Buy	+10,000	New	+$13.1K	﹤0.01%	821

Other funds holding MIRA

CSI

Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return

FAB

First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Cary Street Partners's MIRA Position: Q2 2026 in Review

Cary Street Partners held its MIRA Pharmaceuticals (MIRA) position steady in Q2 2026 at 10,000 shares worth $9.46K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

Cary Street Partners first reported a position in MIRA in Q4 2024 and has held it in 7 quarters since. The position peaked at $15.1K in Q4 2025. 5 funds tracked by Wall St. Rank hold MIRA as of Q2 2026.

Cary Street Partners held 10,000 shares of MIRA Pharmaceuticals worth $9.46K as of Q2 2026.
Cary Street Partners left its MIRA Pharmaceuticals share count unchanged in Q2 2026.
MIRA Pharmaceuticals made up ﹤0.01% of Cary Street Partners's portfolio in Q2 2026, its #1071 holding.
Cary Street Partners first reported a position in MIRA Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Cary Street Partners's MIRA Pharmaceuticals position peaked at $15.1K in Q4 2025.
5 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.